Skip to main content
. 2012 May 1;7(5):e36302. doi: 10.1371/journal.pone.0036302

Figure 5. Dose response and pharmacodynamics of CK-165 in rats with U46619 induced pulmonary hypertension.

Figure 5

CK-165 decreased RVSP rapidly after nebulization at both 5 mg/kg and 30 mg/kg by 20.4±8.6 and 58.2±6.9% at 6 minutes, respectively (p<0.01 compared with baseline). The maximum decrease in RVSP, Emax, observed with CK-165 (75±7.53%) is similar to that seen with the prostacyclin analog, treprostinil (58±8.09%) and the phosphodiesterase 5 inhibitor, sildenafil (61±7.65%).